Phase I Clinical Study of E7389
Phase I Clinical Study of E7389 in Patients With Solid Tumors
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Chiba-prefecture
-
Kashiwa、Chiba-prefecture、日本、277-0882
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Patients with histologically or cytologically confirmed solid tumors.
- Patients who have progressed on or following standard therapy and with no other treatment options.
- Patients aged 20-74 when they give informed consent.
- Patients having a performance status (PS) of Eastern Cooperative Oncology Group (ECOG) 0 or 1.
- Patients who can stay at the hospital from the start of the study drug treatment to 2 weeks of the first cycle.
- Patients having adequate function of major organs (bone marrow, liver, kidney and lungs):
(1) Neutrophil count 1,500/mm3 (2) Platelet count 100,000/mm3 (3) Hemoglobin 9.0 g/dL (4) Aspartate aminotransferase [AST] 2.5 times the upper limits of normal (ULN) in institute, unless related to liver involvement by tumor, in which case 5.0 times ULN (5) Alanine aminotransferase [ALT] 2.5 times ULN in institute, unless related to liver involvement by tumor, in which case 5.0 times ULN (6) Total bilirubin 1.5 times ULN in institute (7) Serum creatinine 1.5 times ULN in institute (8) Pulse oximeter oxygen saturation 90%
7. Patients with no adverse drug reactions (excluding alopecia, etc.) that were caused by the prior therapy or could influence the safety evaluation of the study drug.
The withdrawal periods required from the completion of the prior therapy to the start of the study drug therapy are as follows:
- Chemotherapy (excluding oral 5-FU and molecular target drugs), surgical therapy, other study drugs: 4 weeks
- Nitrosourea agents, mitomycin C: 6 weeks
- Radiotherapy, endocrinotherapy, immunotherapy, oral 5-FU, molecular target drugs, blood transfusion, blood products, G-CSF and other hematopoietic factors: 2 weeks
8. Patients who give written informed consent.
9. Patients with an expected survival of longer than 3 months from the start of the study drug therapy.
Exclusion criteria:
- Patients with systemic infection with a fever (38°C).
- Patients with a large amount of pleural effusion, ascites and pericardial fluid requiring drainage.
- Patients with brain metastasis with clinical symptoms.
- Patients with serious complications: (1) Patients with uncontrollable cardiac disease such as ischemic heart disease and arrhythmia at a level of severity that needs to be treated (excluding left ventricular hypertrophy, mild left ventricular volume overload and mild right leg block that accompany hypertension) (2) Patients with myocardial infarction within 6 months prior to study entry (3) Patients with a complication of hepatic cirrhosis (4) Patients with interstitial pneumonia and pulmonary fibrosis (5) Patients with a bleeding tendency
Women who are pregnant or breastfeeding, or premenopausal women of childbearing potential.
Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Premenopausal women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test, or have not agreed to use adequate measures of contraception.
- Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception.
- Patients who have tested positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV) antibody, or hepatitis B virus surface antigen (HBsAg).
- Patients who need continuous systemic steroid therapy during the study period.
- Patients who need continuous use of phenytoin, carbamazepine, rifampicin and/or barbiturate which induces cytochrome P450 (CYP3A4), a drug-metabolizing enzyme, during the study period.
- Patients who have received extensive radiation therapy (30% or more of bone marrow).
- Patients who refused to receive a supportive therapy of blood transfusion by suppressing bone marrow.
- Patients who are participating in other clinical studies.
- Patients whom the investigator or subinvestigator has judged inappropriate for this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:1个
|
E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle.
The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Subjects Who Experienced Dose Limiting Toxicity (DLT)
大体时间:3 weeks
|
DLT is an adverse drug reaction defined as 1)Grade 4 neutropenia for 5 days, 2)>/=Grade 3 febrile neutropenia, 3)>/=Grade 3 neutropenia requiring iv antibiotics, 4)Grade 4 thrombocytopenia, 5)>/=Grade 3 nonhematologic toxicity, 6)Omission of study drug on Day 8 due to >/=Grade 3 neutropenia or thrombocytopenia or investigator decision.
|
3 weeks
|
|
Maximum Tolerated Dose (MTD)
大体时间:3 Weeks
|
MTD was the lowest dose at which a dose limiting toxicity occurred.
|
3 Weeks
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Safety, Tolerability, the Pharmacokinetics, a Recommended Dose (RD) for Phase II Clinical Study and the Anti-tumor Effect in Evaluable Subjects.
大体时间:3 weeks
|
3 weeks
|
合作者和调查者
调查人员
- 研究主任:Tomio Nakamura、Eisai Co., Ltd.
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.